A Medical Device Daily

Revolutions Medical (RMC; Mount Pleasant, South Carolina) has filed for patent protection in Australia, which finalizes all the countries the company has identified to be the most important for its Rev Vac safety syringe.

China, Japan, Mexico, Canada and Europe international patent applications have already been filed. "As we get closer to the marketing of our proprietary Rev Vac safety syringe, it was clear to us to have our patents protected internationally. With the completion of the Australian filing we feel very comfortable that we have fully protected our syringe from patent infringement and now we look to protect our four U.S. pending patents, internationally, for our proprietary Rev Color MRI and Rev 3D MRI technology," said CEO Ron Wheet.

In June 2007, RMC filed for four U.S. patents for its technology for MRI, including color, 3-D and auto segmentation of images.

"The indications are that our technology claims in our pending four U.S. patents are strong and Rev Med will be filing additional international patent protection in a number of other countries, as well as Europe," says Richard Theriault, president of Strategic Product Development and a consultant to Revolutions Medical.

RMC develops safety-engineered medical devices and provides software solutions and proprietary tools that are compatible with standard MRIs and standard PACS.

In other patent news, Prometheus Laboratories (San Diego) reported the issuance of U.S. patent No. 7,361,733, "Compositions and Methods for the Therapy and Diagnosis of Inflammatory Bowel Disease," which protects a flagellin peptide useful in the detection of antibodies to the flagellin CBir1, or anti-CBir1, for determining the presence of inflammatory bowel disease (IBD).

This proprietary technology is used in the company's Prometheus IBD Serology 7 test and its recently launched Prometheus IBS Diagnostic test. Prometheus has exclusive rights to this technology under an agreement with Corixa.

The patent provides a means of detecting the presence and levels of CBir1 antibodies in a patient sample. About 50% of patients with Crohn's disease have a positive response to anti-CBir1. The presence of anti-CBir1 identifies a subset of patients with Crohn's disease who were not previously detected by other serologic markers.

Before the introduction of anti-CBir1, patients who were pANCA positive may have been diagnosed as having ulcerative colitis. However, anti-CBir1 helps physicians to further characterize pANCA-positive patients and distinguish between ulcerative colitis and ulcerative colitis-like Crohn's disease.

In addition, anti-CBir1 may be associated with more complicated Crohn's disease and with phenotypes involving small bowel disease, such as fibrostenosis and internal perforating disease.

Prometheus Laboratories is a specialty pharmaceutical company.

No Comments